CN102639537B - 吲唑基取代的二氢异*唑并吡啶及其使用方法 - Google Patents

吲唑基取代的二氢异*唑并吡啶及其使用方法 Download PDF

Info

Publication number
CN102639537B
CN102639537B CN201080039898.3A CN201080039898A CN102639537B CN 102639537 B CN102639537 B CN 102639537B CN 201080039898 A CN201080039898 A CN 201080039898A CN 102639537 B CN102639537 B CN 102639537B
Authority
CN
China
Prior art keywords
formula
alkyl
compound
hydrogen
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080039898.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102639537A (zh
Inventor
M·米彻斯
M·福尔曼
A·瓦卡洛波洛斯
K·滋梅曼恩
N·特尤施
M·洛贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN102639537A publication Critical patent/CN102639537A/zh
Application granted granted Critical
Publication of CN102639537B publication Critical patent/CN102639537B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201080039898.3A 2009-07-10 2010-07-07 吲唑基取代的二氢异*唑并吡啶及其使用方法 Expired - Fee Related CN102639537B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09008996 2009-07-10
EP09008996.2 2009-07-10
PCT/EP2010/004147 WO2011003604A1 (en) 2009-07-10 2010-07-07 Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof

Publications (2)

Publication Number Publication Date
CN102639537A CN102639537A (zh) 2012-08-15
CN102639537B true CN102639537B (zh) 2015-07-22

Family

ID=42584913

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080039898.3A Expired - Fee Related CN102639537B (zh) 2009-07-10 2010-07-07 吲唑基取代的二氢异*唑并吡啶及其使用方法

Country Status (7)

Country Link
US (1) US9073939B2 (enExample)
EP (1) EP2451817B1 (enExample)
JP (1) JP5674211B2 (enExample)
CN (1) CN102639537B (enExample)
CA (1) CA2767476A1 (enExample)
ES (1) ES2433228T3 (enExample)
WO (1) WO2011003604A1 (enExample)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082864A1 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
CN1732159A (zh) * 2002-09-10 2006-02-08 拜耳医药保健股份公司 嘧啶酮衍生物作为治疗药物治疗急性和慢性炎性、缺血性和重建性病变
WO2008071451A1 (en) * 2006-12-14 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Dihydropyridine derivatives useful as protein kinase inhibitors
CN101472915A (zh) * 2006-04-19 2009-07-01 诺瓦提斯公司 吲唑化合物和抑制cdc7的方法
WO2009149837A1 (en) * 2008-06-09 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Substituted 4- (indazolyl) -1,4-dihydropyridines and methods of use thereof
WO2009149836A1 (en) * 2008-06-09 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Annellated 4- (indazolyl) -1,4-dihydropyridine derivatives and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635977A (en) 1969-11-03 1972-01-18 American Cyanamid Co Certain 6-trifluoromethylcytosines and thiocytosines their synthesis and their use in the synthesis of uracisls and thiouracil
JP2634640B2 (ja) 1988-07-29 1997-07-30 三共株式会社 縮環ジヒドロピリジン誘導体
DK0379917T3 (da) 1989-01-26 1995-12-11 Bayer Ag Optisk aktive (meth)acrylsyre-drivater, deres fremstilling, deres polymerisation til optisk aktive polymere og disses anvendelse
US5274167A (en) 1989-01-26 1993-12-28 Bayer Aktiengesellschaft Polymeriable optically active (meth) acrylic acid derivatives
DE19546136A1 (de) 1995-12-11 1997-06-12 Bayer Ag Chirale stationäre Phasen für die chromatographische Trennung von optischen Isomeren
JP2003525939A (ja) 2000-03-03 2003-09-02 アボット・ラボラトリーズ 三環式ジヒドロピラゾロン及び三環式ジヒドロイソオキサゾロンカリウムチャンネル開放剤
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
EP1638941B1 (en) * 2003-05-22 2010-06-02 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
WO2005085227A1 (en) 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
EP1722792A1 (de) 2004-03-03 2006-11-22 Boehringer Ingelheim International GmbH Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2006066011A2 (en) 2004-12-13 2006-06-22 Irm Llc Compounds and compositions as modulators of steroidal receptors and calcium channel activities
WO2006074419A2 (en) 2005-01-07 2006-07-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
ATE521608T1 (de) * 2005-11-01 2011-09-15 Array Biopharma Inc Glucokinaseaktivatoren
WO2009006580A1 (en) 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
EP2493873B1 (en) 2009-10-06 2014-04-09 Bayer Intellectual Property GmbH Fluorinated 2,6-dialkyl-3,5-dicyano-4-(1h-indazol-5-yl)-1,4-dihydropyridines and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1732159A (zh) * 2002-09-10 2006-02-08 拜耳医药保健股份公司 嘧啶酮衍生物作为治疗药物治疗急性和慢性炎性、缺血性和重建性病变
WO2005082864A1 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
CN101472915A (zh) * 2006-04-19 2009-07-01 诺瓦提斯公司 吲唑化合物和抑制cdc7的方法
WO2008071451A1 (en) * 2006-12-14 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Dihydropyridine derivatives useful as protein kinase inhibitors
WO2009149837A1 (en) * 2008-06-09 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Substituted 4- (indazolyl) -1,4-dihydropyridines and methods of use thereof
WO2009149836A1 (en) * 2008-06-09 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Annellated 4- (indazolyl) -1,4-dihydropyridine derivatives and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Drug development of MET inhibitors: targeting oncogene addiction and expedience;Paolo M. Comoglio,等;《Nature Reviews Drug Discovery》;20080630;第7卷;第504-516页 *

Also Published As

Publication number Publication date
US9073939B2 (en) 2015-07-07
EP2451817B1 (en) 2013-09-04
WO2011003604A1 (en) 2011-01-13
US20120190709A1 (en) 2012-07-26
CA2767476A1 (en) 2011-01-13
JP2012532170A (ja) 2012-12-13
ES2433228T3 (es) 2013-12-10
EP2451817A1 (en) 2012-05-16
JP5674211B2 (ja) 2015-02-25
HK1174620A1 (zh) 2013-06-14
CN102639537A (zh) 2012-08-15

Similar Documents

Publication Publication Date Title
JP5506788B2 (ja) 置換４−（インダゾリル）−１，４−ジヒドロピリジン類およびそれらの使用方法
JP5480891B2 (ja) アネレート化４−（インダゾリル）−１，４−ジヒドロピリジン誘導体およびそれらの使用方法
CN102348702B (zh) 二环和三环吲唑-取代的1,4-二氢吡啶衍生物及其用途
TW201124396A (en) Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof
JP5753174B2 (ja) フッ化２，６−ジアルキル−３，５−ジシアノ−４−（１ｈ−インダゾール−５−イル）−１，４−ジヒドロピリジン類およびそれらの使用方法
CN102639537B (zh) 吲唑基取代的二氢异*唑并吡啶及其使用方法
JP5571800B2 (ja) フロピリジニル置換１，４−ジヒドロピリジン誘導体およびその使用方法
CN102666525B (zh) 氟取代的2-芳基-3,5-二氰基-4-吲唑基-6-甲基-1,4-二氢吡啶和其用途
HK1174620B (en) Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof
JP2012532170A5 (enExample)
HK1166801B (en) Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof
HK1176615A (en) Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Free format text: FORMER OWNER: BAYER PHARMACEUTICALS AG

Effective date: 20130325

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130325

Address after: German Monheim

Applicant after: Bayer Pharma Aktiengesellschaft

Address before: Berlin

Applicant before: Bayer Pharmaceuticals AG

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1174620

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1174620

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150722

Termination date: 20180707

CF01 Termination of patent right due to non-payment of annual fee